双靶点CAR-T治疗后SLE患者成功自然妊娠并分娩健康新生儿
本报告描述一名24岁IV型狼疮肾炎女性接受BCMA/CD19双靶点CAR-T细胞治疗后,于输注后6个月和21个月自然妊娠,两次妊娠期间狼疮活动度均维持极低且无复发,经阴道足月分娩两名健康女婴。母体血液、母乳、胎盘及新生儿血液的CAR-T细胞DNA检测均为阴性,婴儿生长、神经发育和免疫功能正常。
要点
- BCMA/CD19 CAR-T治疗后SLE患者可实现 sustained 分子缓解并自然妊娠
- 两次妊娠期间狼疮活动度极低、无复发,均为足月阴道分娩健康女婴
- 母体血液、母乳、胎盘及婴儿血液CAR-T细胞DNA检测均阴性,无传播证据
核心结论
- BCMA/CD19 CAR-T细胞治疗可能诱导SLE持续缓解(超过30个月)、保留生育力,并获得健康妊娠与新生儿。
研究设计与样本
- 个案报告:一名24岁IV型狼疮肾炎女性接受BCMA/CD19 CAR-T细胞治疗,监测母体与新生儿样本中CAR-T细胞存在情况及婴儿健康。
主要发现
- 患者于CAR-T输注后6个月和21个月自然妊娠,两次妊娠期间狼疮活动度均维持极低且无复发,均足月阴道分娩健康女婴。
- 患者血液、母乳、胎盘及婴儿出生时与随访期血液的连续数字PCR分析CAR-T细胞DNA均为阴性,两名婴儿随访中生长、神经发育与免疫功能正常,无CAR-T细胞传播证据。
- 患者自报生活质量在治疗后也显著改善。
关键数值与推荐
- 持续缓解超过30个月;两次妊娠分别为输注后6个月和21个月自然受孕;CAR-T细胞DNA检测在母体血液、母乳、胎盘及婴儿血液中均阴性。
临床怎么用
- 提示CAR-T治疗后SLE患者可能保留生育力并安全妊娠,但需个体化评估并为考虑妊娠的患者制定循证指南。
局限性
- 为单例个案报告,结论不能外推至所有SLE患者,仍需更多证据支持妊娠时机与安全性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dual-target CAR-T cell therapy targeting BCMA and CD19 is an emerging and promising treatment for systemic lupus erythematosus (SLE). However, its effects on fertility and neonatal safety are largely unknown. This report describes the outcomes of two successful pregnancies and deliveries in a patient with SLE treated with BCMA/CD19 CAR-T cell therapy. METHODS: A 24-year-old woman with class IV lupus nephritis received BCMA/CD19 CAR-T cell therapy. The patient achieved sustained molecular remission of SLE and became pregnant spontaneously at 6-months and 21-months postinfusion. We monitored for CAR-T cell presence in maternal and neonatal samples and assessed the health of the infants. RESULTS: Lupus activity remained minimal without flares throughout both pregnancies. The patient had two term vaginal deliveries of healthy female infants. Serial digital polymerase chain reaction analysis of the patient's blood, breast milk, and placenta, as well as the infants' blood at birth and during follow-up, were all uniformly negative for CAR-T cell DNA. Both infants showed normal growth, neurodevelopment, and immune function at follow-up, with no evidence of CAR-T cell transmission. The patient's self-reported quality of life also improved significantly after the therapy. CONCLUSION: This case suggests that BCMA/CD19 CAR-T cell therapy may induce sustained remission (over 30 months) in SLE, preserve fertility, and result in healthy pregnancies and neonates. This finding highlights the need for evidence-based guidelines for patients considering pregnancy after CAR-T cell therapy.
引用
- Jiang Q, Wang M, Wang M, et al. Successful Spontaneous Pregnancies and Healthy Neonates After Dual-Target CAR-T Cell Therapy in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2026. PMID: 41669912. doi:10.1002/art.70070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。